Premium
Pulmonary function testing and pulmonary Langerhans cell histiocytosis
Author(s) -
Bernstrand Cecilia,
Cederlund Kerstin,
Henter JanInge
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20707
Subject(s) - medicine , pulmonary function testing , diffusing capacity , vital capacity , lung volumes , interstitial lung disease , radiology , lung , pulmonary diffusing capacity , high resolution computed tomography , langerhans cell histiocytosis , nuclear medicine , stage (stratigraphy) , cardiology , lung function , disease , paleontology , biology
In a long‐term single‐center follow‐up (median 16‐years), we studied high‐resolution computed tomography (HRCT) and pulmonary function testing (PFT) in pulmonary LCH. Diffusing capacity corrected for alveolar volume (K(CO)) and total lung capacity (TLC) were significantly decreased ( P = 0.016 and P = 0.030, respectively) in patients with extensive HRCT abnormalities. Patients with late stage disease on HRCT had increased forced expiratory volume (FEV 1.0 )( P = 0.037) and vital capacity (VC)( P = 0.036). Disease monitoring is important in pulmonary LCH, and since PFT with diffusing capacity provides a measurement of the current lung function, it may be a valuable tool in monitoring pulmonary LCH, and a good complement to imaging. Pediatr Blood Cancer 2007;49:323–328. © 2005 Wiley‐Liss, Inc.